Press Releases

CARLSBAD, Calif., Jan. 9, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced the appointment of Onaiza Cadoret-Manier as chief corporate development and commercial officer reporting to Brett P. Monia, Ph.D., chief executive officer. In

BOSTON, Jan. 9, 2020 /PRNewswire/ -- David Hines, CEO and Founder of clinical advocacy firm ConsumerMedical, announced today the closing of an equity inves

ROCKVILLE, Md., Jan. 9, 2020 /PRNewswire/ --RGX-314 programs for treatment of wet AMD and diabetic retinopathy continue to advance Plans to initiate a pivotal program of subretinal delivery for wet AMD in 2H 2020, following the 12-month assessment of Cohort 5 patients in the Phase I/IIa trial FDA removes partial

TARRYTOWN, N.Y., Jan. 9, 2020 /PRNewswire/ -- Approximately 25% decrease in total bone lesions (both new and existing) driven by nearly 90% reduction in formation of new lesions in patients with fibrodysplasia ossificans progressiva (FOP) Regeneron plans to discuss regulatory submission with regulatory authorities; pediatric trial planning un

SAN DIEGO, Jan. 9, 2020 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replaceme

CEDAR KNOLLS, N.J., Jan. 9, 2020 /PRNewswire/ -- MYOS RENS Technology, Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lea

SOUTH SAN FRANCISCO, Calif., Jan. 9, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that the company will present at the 38th Annua

TOKYO, Jan. 9, 2020 /PRNewswire/ -- Healios K.K. ("the Company"); (TSE: 4593), Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative therapies announces that its Chairman and Chief Executive Officer, Hardy TS Kagimoto, MD, will provide a strategic overview and company update at the 38

SAN DIEGO and CALGARY, Alberta, Jan. 9, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that ROTH Capital Partners (ROTH) will conduct a Key Opinion Leader call today at

HOLON, Israel, Jan. 9, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today provided an update on upcoming milestones for its COM701 and COM902 clinical programs and highlighted 2019 accom